Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.

نویسندگان

  • Irit Bahar
  • Igor Kaiserman
  • Penny McAllum
  • David Rootman
  • Allan Slomovic
چکیده

PURPOSE We report on the use of subconjunctival bevacizumab on corneal vessel density in recurrent pterygia. METHODS The charts of 5 patients with recurrent pterygium, who received subconjunctival injections of bevacizumab (2.5 mg/0.1 ml) were retrospectively reviewed. Ophthalmic evaluation included Snellen visual acuity (VA), tonometry and complete examination before the injection and at 1 week and 1 and 3 months thereafter. Digital photographs of the eyes were analyzed by image analysis software to determine the area of cornea covered by new vessels as a percentage of the total corneal area. RESULTS No ocular or systemic adverse events were observed. No change in visual acuity was noted in any patient following the injection. The mean change in corneal vascularization after one bevacizumab injection was 0.03%+/-0.45, while after two injections the change was 0.025%+/-0.19 (both not statistically different than zero, t-test). CONCLUSIONS Short-term results suggest that subconjunctival bevacizumab is well tolerated but does not cause regression of corneal vessels in recurrent pterygium.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium

PURPOSE To assess the effect of single versus multiple subconjunctival ranibizumab injections in patients with an early pterygium recurrence. SETTING Single-center, academic practice. STUDY POPULATION Nine patients with early pterygium recurrence. OBSERVATIONAL PROCEDURE Subconjunctival ranibizumab (0.5 mg/0.05 mL) was administered adjacent to pterygium recurrence. Group 1 (n = 5) receive...

متن کامل

Is Bevacizumab Effective in Inhibiting the Growth of Recurrent Pterygium?

Objective: The objective of this selective EBM review is to determine whether or not Bevacizumab is an effective treatment in inhibiting the growth of recurrent pterygium. Study Design: Review of three published, English language randomized controlled trials published in 2010, 2012, and 2013. Data sources: Three randomized controlled trials measuring the efficacy of Bevacizumab to inhibit the g...

متن کامل

Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment

Vascular endothelial growth factor inhibitor is an emerging therapeutic modality for various ocular diseases with neovascularization (NV). However, for corneal NV, controversy remains regarding whether bevacizumab or ranibizumab is superior. A 32-year-old female diagnosed with herpetic keratoconjunctivitis with refractory corneal NV despite two previous subconjunctival and intrastromal bevacizu...

متن کامل

Subconjunctival Bevacizumab Injection in Treatment of recurrent Pterygium

Objective: to determine the clinical effect of subconjunctival injection of bevacizumab in regression or halting growth in patients with recurrent pterygium. Method and materials: The study was an off-label; 2-dosing, interventional case series involving 20 patients with recurrent pterygium. They received subconjunctival bevacizumab (0.2ml/ 2.5mg). vascularity and thickness of Pterygium was gra...

متن کامل

Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization.

PURPOSE To compare the effects of bevacizumab applied either subconjunctivally or topically, in a rat model of corneal neovascularization induced by alkali burn. METHODS The right corneas of 24 Wistar-Albino rats were cauterized with silver nitrate sticks. The rats were divided randomly and equally into three groups: no treatment control (n=8), subconjunctival bevacizumab treatment (n=8), and...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Current eye research

دوره 33 1  شماره 

صفحات  -

تاریخ انتشار 2008